CCT241736

CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3 (D835Y) (Kd, 14 nM) .

Product Specifications

CAS Number

[1402709-93-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Aurora Kinase; FLT3

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CCT241736.html

Concentration

10mM

Purity

99.88

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1=NN(C)C=C1C2=NC3=C(N4CCN(CC5=CC=C(Cl)C=C5)CC4)C(Cl)=CN=C3N2

Molecular Formula

C22H23Cl2N7

Molecular Weight

456.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Bavetsias V, et al. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem. 2012 Oct 25;55 (20) :8721-34.